

REMARKS

Applicants submit herewith an initial Sequence Listing in computer and paper form, in accordance with 37 C.F.R. §1.821-1.825. The content of the paper and computer-readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same and do not include new matter.


Amendments have been made to the specification to insert a sequence identifiers throughout the specification. Applicants submit that no new matter has been introduced by the amendments to the specification. Support for the amendments is found in the specification and claims as originally filed.

Applicants also submit herewith twenty-seven (27) sheets of replacement drawings. The Notice indicates that Figure 1 contains excessive text. In response, applicants have amended Figure 1 to delete the text as shown in the attached annotated sheet of Figure 1. Applicants submit that no new matter has been introduced by the amendments to Figure 1.

In addition, the Notice indicates that Figures 2A-2D and 7 are not reproducible and must be submitted on flexible strong, white, smooth, non-shiny and durable. Applicants submit the replacement sheets on the requested paper.

Applicant requests a one month extension of time and encloses herewith the requisite fee as set forth in 37 C.F.R. § 1.17(a)(1). Applicant does not believe that any additional fee is required in connection with the submission of this document. However, should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Rochelle K. Seide
PTO Registration No. 32,300

Carmella L. Stephens
PTO Registration No. 41,328

Attorneys for Applicants

BAKER BOTTS, L.L.P.
30 Rockefeller Plaza
New York, NY 10012-4498
(212)-408-2500

FIGURE 1

Different SMaRT Reactions




Figure 1. Schematic representation of different SMaRT reactions. (a) *Trans-splicing* reactions between the target 5' splice site and PTMs 3' splice site; (b) *Trans-splicing* reactions between the target 3' splice site and PTMs 5' splice site and (c) Replacement of internal exon by double *trans-splicing* reaction in which the PTM carry both 3' and 5' splice sites. BD, binding domain; BP, branchpoint sequence; PPT, polypyrimidine tract and ss, splice sites.